Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.
Pacira Pharmaceu (NASDAQ:PCRX) traded in a range yesterday that spanned from a low of $47.32 to a high of $51.30. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of...
Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.
PARSIPPANY, N.J. (AP) _ Pacira Pharmaceuticals Inc. (PCRX) on Thursday reported a fourth-quarter loss of $4.9 million, after reporting a profit in the same period a year earlier.
-- Full-year 2019 revenue increases 25 percent to $421 million versus 2018 --
Count on these top-ranked stocks that are likely to beat earnings estimates in their next releases.
Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.
Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2019 financial results before the open of the U.S. markets on Thursday, February...
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...
As of late, it has definitely been a great time to be an investor in Pacira BioSciences.
Investors in Pacira BioSciences Inc saw new options become available this week, for the March 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PCRX options...
The Zacks Analyst Blog Highlights: Meritage Homes, Cable One, GoDaddy, Pacira and Great Lakes Dredge
Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...
The Zacks Analyst Blog Highlights: GoDaddy, Great Lakes Dredge, LPL and Pacira BioSciences
Trump touted stock market's record run in the State of the Union speech, and painted a rosy picture of the economy. Given the positives, investing in growth stocks won't be a bad proposition.
The People's Bank of China offered funds in the overnight market to the tune of $71 billion for the second successive day to alleviate the economic stress of containing the viral outbreak.
Pacira BioSciences has been struggling lately, but the selling pressure may be coming to an end soon.
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.